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charge a fee of R35.00 for this service. CONCLUSIONS: PIT is an important service 
that pharmacists deliver where the need exists. It is recommended that pharmacists be 
encouraged to counsel patients thoroughly when delivering a PIT service.
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AN ANALYSIS OF DRUG COST CONTAINMENT POLICY AT A 
HOSPITAL IN SOUTHERN THAILAND
Sae Wong AK, Kunthavaporn S, Junchareon N
Songkhla Hospital, Muang, Songkhla, Thailand
OBJECTIVES: To examine drug cost containment policy implemented at a hospital in 
southern Thailand. METHODS: This study was a retrospective, pre-post policy inter-
vention descriptive design. During the ﬁ scal years of 2005 and 2009, various drug cost 
containment strategies, including generic substitution for any drug group and a success-
ful treatment guideline for orthopedic drugs, were adopted at a hospital in southern 
Thailand. Drug expenditures across those ﬁ scal years were examined. The expenditure 
proportions between drugs listed and unlisted in National Essential Drug List were 
calculated. Cost-saving analysis of all generic substitution was conducted. Since the 
treatment guideline for orthopedic drugs was available in the hospital, their expenditures 
were also examined. RESULTS: Total drug expenditures had increased with decreasing 
rate across the study years. It increased by 47.15% from year 2005 to 2006, 43.19% 
from year 2006 to 2007, 21.17% from year 2007 to 2008 and 2.17% from year 2008 
to 2009. The expenditures of essential drugs in the National Drug List were accounted 
for 61.64%, 56.62%, 54.38%, 48.67% and 50.94% across those study periods, respec-
tively. Results showed that generic drug substitution policy reduced overall drug expen-
ditures by 34.33%, or 7.66 million baths from year 2008. In 2009, only 11 items of 
generic drug substitution for branded-name drugs could reduce drug expenditures by 
13.33%, or 4.73 million bahts which reﬂ ected annual cost-saving about 25.95 million 
bahts. In the same year, a result showed that the implementation of orthopedic drug 
guideline reduced drug expenditures by 5.53% or 2.10 million bahts. CONCLUSIONS: 
The study indicated that treatment guideline and generic drug substitution policies could 
control relatively high amount of drug expenditures at a hospital in southern Thailand. 
Hospital administrators should consider to continue these policies.
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OBJECTIVES: The aim of this study was to asess the annual health insurance reim-
bursement of of dental health service in Hungary. METHODS: The assessment base 
of the study was the annual reports of National Health Insurance Fund Administration 
(OEP). Only the data collected from the services in conctractual relationship with the 
OEP and delivered in 2008 were evaluated. Dental care services are organised in dif-
ferent levels: general dental service, specialist dental care, special dental care on uni-
versity level and inpatient departments. Our study covers primary, outpatient and 
hospital dental care. RESULTS: Dental care was supplied by 3378 general and special-
ist dental care services until the end of 2008. For the hospital treatment of more serious 
cases 17 inpatient department is available with 154 patient beds. Within the period 
of examination (2008) 7.6 million cases or rather 23.6 million interventions were 
carried out. The health insurance expenditures of the OEP for outpatient dental care 
was 23.9 billion forints (c85,18 million). The total health insurance reimbursement 
of dental care (including primary, outpatient and hospital care) was 24.92 billion 
Hungarian forints (c88.82 million) in 2008. CONCLUSIONS: The health insurance 
reimbursement of dental care services in Hungary is approximately 2% of the total 
health insurance expenditure of OEP.
PHP59
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OBJECTIVES: There is a known concern of health researchers and public managers in 
Brazil with the population’s access to medicines. We quantiﬁ ed the public expenditure 
on medicines in Brazil, during the period of 2005 to 2008. METHODS: The expenditure 
on medicines comes from a data warehouse of the Ministry of Planning, Budget and 
Management that stores the information concerning any purchase made by the Brazilian 
Federal Government. We also computed the amounts transferred to ofﬁ cial laboratories 
to produce medicines. Information on the states, Federal District and municipalities 
came from the Information System on Public Health Budget (SIOPS). RESULTS: In the 
period 2005 to 2008, the public spending with drugs rose from US$ 1.8 billion to US$ 
2.0 billion in real terms, with an average annual growth equivalent to 3%. The average 
spending in this period was US$ 1.8 billion. Most of the spending on medicines is 
attributed to the Federal Government, with values exceeding US$ 835 million per year. 
Just under half of the expenditure is given to states and municipalities. Considering only 
the federal spending, the “strategic component” represents the largest share, with par-
ticipation from 56%–64% in the period. This result is expected, since the Ministry of 
Health is responsible for funding all the medicines from the “strategic component” of 
pharmaceutical care which includes, among others, the antiretroviral drugs and blood 
products. The amounts of transfers to ofﬁ cial laboratories ranged between 20–25% of 
drug costs. CONCLUSIONS: The expenditure for those pharmaceutical care programs 
whose purchases are centralized at the federal Ministry of Health, didn’t show a signiﬁ -
cant increase in the period of 2005–2008. Rather, the evidence suggests relative stability 
of procurement of medicines from pharmaceutical care programs under the Federal 
Government’s responsibility in this period.
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OBJECTIVES: The aim of our study is to calculate the average health insurance reim-
bursement of spa treatment according to counties in Hungary. METHODS: Data were 
derived from the Hungarian National Health Insurance Fund Administration (OEP) and 
covers the ﬁ scal year of 2007. These data was analyzed in the light of different value of 
its average point. The Hungarian spa ﬁ nancing method is based on relative system, 
which is depending on the treatment’s price. We calculated the average health insurance 
subsidy per of spa treatment (HIS/STN) as an indicator of average health insurance 
reimbursement of a single spa treatment. RESULTS: In 2007 the number of spa treat-
ment was 8,160,438 and the full treatment expenditure of subsidy was 4.34 billion HUF 
(US$25,632 million). The average value of (HIS/STN) was 540,000 HUF (US$3124). 
Two outlier points are the region of North Hungarian Plan (different from average HIS/
STN value was −6.76%) and region of North Transdanubia (different from average 
HIS/STN value was 12.47%). The other regions performed similar outcomes ratio 
between 1.33% and 2.95%. CONCLUSIONS: The main cause of the two outlier 
regions is the inadequat structure of Spa services. Less people visit to North Transda-
nubian Region, because the number of spa facilities isn’t signiﬁ cant, but these thermal 
baths are signiﬁ cant, which price is higher. The North Hungarian Plan attracts a lot of 
patients with lower price. The result if the price is lower, the subsidy will be lower 
because of the ﬁ nancing system is based on relative method.
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OBJECTIVES: Achieving Market Access for new products has become complex for 
pharmaceutical companies. Faced with growing expenditure, health care authorities 
accept or propose various Market Access Agreements (MAA) (risk-sharing/perfor-
mance-based/commercial schemes) but often with little experience and knowledge. We 
performed in-depth analysis of their design and we formulate recommendations to 
stakeholders. METHODS: MAA is a formalized compromise between payers and 
industry to achieve: Price and Reimbursement, HTA recommendation and Formulary 
listing. We reviewed published and grey literature from major health insurers in 
France, Italy, Germany and UK. We conceptualize MAA typology according to the 
nature of uncertainty perceived by stakeholders and their motivations. RESULTS: We 
identiﬁ ed above 30 MAAs and classiﬁ ed them as follows: 1) Value for money not 
questioned: a) Conditional Market Access Agreement: Evidence development 
agreement→Aim: address actual uncertainty; b) Health Outcome Boostering Agree-
ment: Disease Management Initiative→Aim: improve competitive advantage; 2) Value 
for money questioned: a) Cost Containment Agreement: Basic commercial 
agreement→Aim: reduce/control drug bill; b) Health Outcomes Agreement: Value 
based agreement→Aim: link payment to performance. Motivations of public payers: 
Main: Buy health production; Other: Control expenditure; Improve ICER of expensive 
products; Prevent media coverage of negative decision; Provide patient access; Expand 
beneﬁ ts basket. Motivations of the industry: Main: Achieve Market Access for a 
product at high price in all markets; Other: Mitigate development failure; Reassure 
share holders; Improve company publicity; Fulﬁ l requirements of authorities. In UK 
the design of MAA was a direct consequence of formalized HTA, in Italy there was 
no apperent rationale. CONCLUSIONS: Commonly used nomenclature needs to be 
revisited. Applying our typology framework should allow health care payers and the 
industry to design and implement MAAs rationally and with transparence. MAAs in 
UK are a direct repercussion of a not favorable primary HTA.
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OBJECTIVES: ISPOR, iHEA, and HTAi regularly organize congresses in the ﬁ eld of 
health economics. Given the number of abstracts accepted each year it is crucial to assess 
their credibility and how results of cost-effectiveness analyses differ across meetings. 
METHODS: We collected all abstracts published 2007–2009 at ISPOR (International 
and Europe), HTAi and iHEA meetings. Abstracts on cost comparison, cost of treat-
ment, cost beneﬁ t, cost consequences, cost-effectiveness, cost minimization and cost 
utility analyses were reviewed in depth according to a reading grid which allowed 
extraction of essential information that could enable evidence-based decision-making in 
health policy. This included e.g. availability of key methodological parameters, involve-
ment of the industry in authorship and details of conclusions. RESULTS: We analyzed 
5488 abstracts from ISPOR, 1410 from HTAi and 1969 from iHEA. Our preliminary 
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results show that cost-effectiveness studies constituted 15%, 12% and 7% of all 
abstracts presented at ISPOR, iHEA and HTAi respectively. Non-drug technologies 
ranged from 11% at ISPOR to nearly 30% for HTAi and were excluded. 32% of analy-
ses used best standard of care as comparator and 10% did not specify the comparator. 
Approx. Twenty percent of abstracts did not report discount rates, 28% the nature of 
costs included in analysis and 10% the time horizon. a total of 52% of analyses reported 
results as a point estimate of cost per QALY. 15% of abstracts submitted to ISPOR 
were not co-authored by the industry, 50% at HTAi and above that at iHEA. Analyses 
which judged the assessed drug to be cost-effective, cost-saving or dominant made up 
82%, 70% and below 50% at ISPOR, HTAi and iHEA respectively. CONCLUSIONS: 
ISPOR is a congress preferred by the industry and a high proportion of abstracts 
reported favourable conclusions. This trend diminished for HTAi and further for iHEA. 
The quality of abstracts is not satisfactory for informed decision-making.
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OBJECTIVES: Due to the ﬁ nancial crisis Greece was forced to implement hard cost 
containment measures almost in all ﬁ scal sectors. The objective of the study is to inves-
tigate the economic impact emerging from the initiation of controls in prescriptions, 
implemented in the Greek social security funds as of 1st January 2010 to 30th April 
2010. METHODS: The data derive from the drug reimbursement database of the three 
biggest social security funds of Greece from January to April 2010 comparing with the 
same period of the previous year. The three security funds of the analysis cover about 
90% of the greek population with almost 10 million fully insured members. The security 
funds in scope were the following: IKA which covers the private sector with 6.3 million 
insured members; OPAD covering the public sector with 1.5 million insured members; 
OGA for agriculture with 2 million insured patients. RESULTS: In the ﬁ rst four-month 
period of 2010 form the initiation of the prescription control system the pharmaceutical 
expenditure was the following: for IKA c747 million in comparison to 716 million the 
same period in 2009, difference of 4.25%, for OPAD 172 million for 2010 whilst in 
2009 the expenditure was 203 million, with savings of 15% and for OGA in 2010 was 
310 million and the same period in 2009 the amount reimbursed for medicines was 
c288 million with 7.64% growth. It should be highlighted that although for IKA and 
OGA the pharmaceutical expenditure is higher in 2010 in comparison to 2009, still the 
growth of expenditure follows a downward slope, 2008–2009 14.82% for IKA and 
11.64% for OGA respectively. CONCLUSIONS: The new cost containment measures 
implemented in the greek health care sector started presenting results. Other cost con-
tainment implemented measures were price cuts for all medicinal products in May 2010 
and reduced supply prices for sanitary products.
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OBJECTIVES: In the wake of the 2007 Ofﬁ ce of Fair Trading (OFT) Pharmaceutical 
Price and Regulation Scheme (PPRS) market study there is a debate whether the UK 
should switch to a value-based pricing (VBP) scheme. The OFT VBP system has its aim 
to price pharmaceuticals in line with their clinical effectiveness. METHODS: The switch 
from the traditional PPRS system to a VBP scheme in the UK was investigated with 
regards to the two main PPRS objectives: cost containment and value for money. This 
was carried out by modifying and applying a price quantity setting model (Das, 1980) 
to ﬁ t the UK pharmaceutical market and investigate the capital labour ratio of a ﬁ rm. 
The model uses the assumptions that Von Neumann-Morgenstern 4 utility axioms are 
satisﬁ ed, the PPRS proﬁ t cap is binding and that the price set in the VBP scheme is 
efﬁ cient. RESULTS: This paper ﬁ nds that a traditional PPRS, compared to a VBP system, 
might cause overinvestment in capital in proportion to labour resulting in higher than 
necessary production cost, also called the Averch-Johnson effect. The incentive to 
overinvest in capital is found to lie in the link between capital and the proﬁ t cap. We 
show that manipulating the proﬁ t cap by adding non-producing capital, i.e. rate-base-
padding, is only incentivised when marginal productivity of capital is smaller than the 
cost of capital, net the capital allowance. The VBP effect on cost-containment is found 
to be ambiguous; if current pharmaceuticals are priced below what is warranted by their 
clinical effectiveness, cost may actually increase. CONCLUSIONS: This paper ﬁ nds that, 
based on a price-quantity model assessment, a VBP system should be introduced. It 
would increase social welfare by pricing pharmaceuticals equal to the beneﬁ t they 
provide, and thus allocate NHS resources to their best possible use.
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OBJECTIVES: A survey was carried out to investigate the economical impact of a 
switch from the traditional Pharmaceutical Price Regulation Scheme (PPRS) system to 
a value-based pricing scheme (VBP), as proposed by the Ofﬁ ce of Fair Trading (OFT). 
The OFT VBP system has its aim to price pharmaceuticals in line with their clinical 
effectiveness. METHODS: Interviews were carried out with experts from the industry, 
academia and the government comparing the traditional PPRS with the proposed VBP 
system. The interviews focused on the regulatory effectiveness, competition, launch 
delays, pharmaceutical pricing, risk-sharing agreements and uncertainty premium of 
the two systems. a systematic literature review was also carried out for all the above 
mentioned topics. RESULTS: In the interviews the current PPRS system was seen as 
very beneﬁ cial with high transparency and stability, nevertheless lacking mechanisms 
promoting price competition when compared to the VBP system. The main concern 
with a switch to a VBP system was the risk of a global price lock-in. Since the UK is 
directly or indirectly inﬂ uencing pricing decisions within about 25% of global phar-
maceutical consumption, the industry might delay drug launch in the UK, to maintain 
global pricing ﬂ exibility (e.g. in the adjuvant setting). Risk-sharing agreements were 
found to be one possible solution to maintain global price ﬂ exibility for the industry, 
while ensuring the NHS pays a fair price. The interviewed were unanimous about 
establishing an organization separate from any political inﬂ uences needs to handle the 
pricing decision to avoid conﬂ icting incentives. It was suggested to offer a price 
premium for pharmaceuticals with well documented cost-effectiveness. a premium 
would incentivise the industry and reduce reimbursement decision uncertainty. CON-
CLUSIONS: This survey indicates that a transparent and stable pricing process with 
proper risk-sharing agreements would increase the probability of a successful imple-
mentation of a VBP system in the UK.
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OBJECTIVES: HTAs are frequently required to assess different treatment regimes for 
different disease types. Frequently, technology appraisal decisions are based on the 
ICERs estimated from economic models. The aim of this study was to identify any trends 
in accepted ICER thresholds by disease type. METHODS: All published technology 
appraisals since April 2005 were downloaded from PBAC, SMC, CADTH, and NICE 
websites. Appraisals were categorised by disease type according to BNF categories. The 
manufacturer’s base-case ICERs were extracted and compared across accepted submis-
sions by disease type. RESULTS: Eighteen CADTH, 122 SMC, 81 PBAC and 122 NICE 
appraisals were identiﬁ ed. For PBAC and SMC, the accepted ICER level (<$75,000 and 
<£30,000, respectively) was consistent across >90% of the disease categories. However, 
accepted ICERs for malignant disease cluster at a higher level (up to $200,000 for PBAC 
and up to £63,000 for the SMC). Additionally, age related macular degeneration for 
PBAC, and severe osteoporosis, Lennox-Gastaut syndrome, plaque psoriasis, and hyper-
ammonaemia for the SMC have treatments with accepted ICERs outside the typical 
range. Data is limited for CADTH, although Crohn’s disease and hepatitis B are excep-
tional in having treatments with accepted ICERs >$80,000. Complex data from NICE 
is qualitatively assessed in light of data from the other HTAs. Whilst most accepted 
ICERs were below £30,000, selected submissions for malignant disease were accepted 
above this commonly assumed threshold. CONCLUSIONS: Across disease types, 
accepted ICERs tend to cluster beneath a common threshold. However, submissions for 
treatments of malignant disease and immunosuppression have a greater chance of 
acceptance at higher ICERs than submissions for other disease categories. Rare diseases 
may also have a higher limit for ICER acceptance.
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PRIMARY CARE DATA RECORDING?
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OBJECTIVES: The Quality and Outcomes Framework (QOF) was introduced in the 
UK in April 2004. The scheme ﬁ nancially rewards practices for providing quality care 
and this is evaluated based on electronic medical records. This study therefore evalu-
ated whether data recording changed after QOF was introduced. METHODS: Patients 
were selected from The Health Improvement Network (THIN) database, which holds 
longitudinal anonymised primary care records from >450 UK practices. Patients were 
grouped according to whether they ever had ≥1 of 15 chronic QOF diseases. Percent-
ages of patients with ≥1 general practice (GP) visit, smoking status, blood pressure 
(BP) and weight record were estimated throughout nine 12-month time periods 
(January 4, 2000-January 4, 2009). T-tests compared mean percentages before and 
after QOF introduction (January 4, 2004). RESULTS: Percentage of QOF patients 
ranged from 26.6% to 32.9% over time and non-QOF patients from 67.1% to 73.4%. 
The average percentage of QOF patients with a GP visit was 80.5% (standard devia-
tion (SD):3.2) before QOF and 84.5% (SD:0.9) after QOF (p = 0.086). These percent-
ages were 57.5% (SD:3.5) and 62.0% (SD:0.6) (p = 0.082) for non-QOF patients. 
The average percentages for smoking recording were 26.8% (SD:12.9) versus 55.9% 
(SD:3.0) (p = 0.018) for QOF patients and 10.9% (SD:4.8%) versus 22.3% (SD:2.9) 
(p = 0.010) for non-QOF patients. For BP recording, 53.6% (SD:6.7) versus 68.1% 
(SD:4.8) (p = 0.013) for QOF patients and 20.5% (SD:2.9) versus 24.2% (SD:0.9) (p 
= 0.084) for non-QOF patients. For weight recording, 25.5% (SD:5.4) versus 40.4% 
(SD:3.2) (p = 0.006) for QOF patients and 9.8% (SD:1.7) versus 14.8% (SD:1.7) (p 
= 0.004) for non-QOF patients. CONCLUSIONS: Overall, the proportion of GP visits 
and clinical recording increased after QOF was introduced, although there was no 
evidence of a difference for GP visits or BP in non-QOF patients. This suggests that 
QOF inﬂ uenced recording, especially the recording of the evaluated clinical measures 
for patients with chronic QOF diseases.
